Logo Image
Feature|Videos|July 18, 2024

Lessons from Vaccine Development and Future Possibilities

The panel discusses the rapid development of mRNA vaccines, the opportunities for mRNA technology to revolutionize drug discovery and gene therapy, and the need for regulatory collaboration to enable efficient review and access to these innovative treatments.

Episodes in this series

The rapid progress in mRNA technology has the potential to revolutionize drug development, with speakers emphasizing the need for collaboration, innovation, and regulatory flexibility to accelerate its adoption. They highlighted the technology's versatility and speed, as well as its potential to create a new therapeutic paradigm. Educating other countries about this technology and facilitating global distribution, particularly in the rare disease space, were also discussed.

Discussion Topics

  • 0:00 - Success of mRNA vaccines and opportunities to leverage this for other mRNA-based therapies
  • 0:29 - Promoting collaboration and innovation in drug development using mRNA technology
  • 0:41 - Extracting best practices from mRNA vaccine development to accelerate other mRNA therapies
  • 1:41 - Encouraging risk-based regulatory approaches to facilitate timely access to mRNA therapies
  • 3:52 - Using mRNA for rapid target evaluation and validation in early drug development
  • 5:03 - Advances in mRNA technology for site-specific genomic insertion and gene therapy
  • 7:55 - Regulatory reliance and collaboration across countries to enable efficient review of rare disease mRNA treatments

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more